Cargando…
Serum lipoprotein(a), and plasminogen activator inhibitor-1 in uncomplicated type 2 diabetes mellitus: a case–control study
Increased levels of lipoprotein (a) [Lp(a)] are indicative of coronary artery disease (CAD). Dyslipidemia, which is an established risk factor for CAD, is also an additional adverse effect of uncontrolled type 2 diabetes. Procoagulant and fibrinolytic indicators have been linked to the development o...
Autores principales: | Abdullah, Fargeen E., Ahmed, Sardar N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405991/ https://www.ncbi.nlm.nih.gov/pubmed/37554894 http://dx.doi.org/10.1097/MS9.0000000000000915 |
Ejemplares similares
-
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
por: Jasmiad, Nurbadriah binti, et al.
Publicado: (2022) -
Role of increased plasminogen activator inhibitor-1 and vitronectin in gestational diabetes mellitus
por: Ozgen, Levent, et al.
Publicado: (2023) -
Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects
por: Al-Hamodi, Zaid, et al.
Publicado: (2012) -
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
por: Al-Hamodi, Zaid, et al.
Publicado: (2011) -
Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus
por: Canecki-Varžić, Silvija, et al.
Publicado: (2016)